News

The technology concerns medicines such as diazepam (valium), ibuprofen and the cholesterol-reducing fenofibrate and the research will enable lower doses and reduce the chance of side effects. Applying

BioSpecifics Technologies’ operating loss was $323,128 for the fourth quarter of 2010, compared to $729,219 for the same period in 2009. The company has generated net income of

SPN-812 is a selective norepinephrine reuptake inhibitor, which, according to Supernus, could be more effective and have a better side effect profile than other non-stimulant treatments for ADHD

The randomised, open-label, phase II study evaluated the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also evaluated once weekly (exenatide extended-release for

CellJammer discovery technology helps in discovering and developing new biopharmaceuticals. ProtAffin claims the technology enables the company to discover and develop biopharmaceuticals with a novel mechanism of action

Otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, is a targeted T cell immunotherapy being developed for the treatment of type 1 diabetes and other autoimmune diseases. Following preliminary

The company expects to recruit around 120 patients at approximately 20 centers in the US and Canada. The study is designed to demonstrate a reduction in plaque inflammation

Under the pact, CTI is expected to initiate a Phase III trial in US and Europe in elderly patients with relapsed or refractory acute myeloid leukemia (AML) for

GLPG0187 was developed for metastatic cancer. In the trial, Galapagos expects to involve patients with solid tumor s and patients with confirmed diagnosis of advanced, recurrent, or metastatic